It also intrigued a sense of investigating GZMB as a potential drug target, especially for the niche subpopulation identified across the RA (cluster 1) and CAD (cluster C) patients wherein GZMB was under-expressed. This evidence concerns the gene GZMB and rheumatoid arthritis.